Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mikalai Katsin
Institutions:
Universitat Autònoma de Barcelona,
Lithuanian Geological Survey
Observed institutions:
Universitat Autònoma de Barcelona,
Lithuanian Geological Survey
OpenAlex ID:
A5060611701
CAR-T Cell Therapy for Classical Hodgkin Lymphoma
2023
·
Mikalai Katsin
, Dmitri Dormeshkin
, et al.
·
HemaSphere
·
20
Isolation of an escape-resistant SARS-CoV-2 neutralizing nanobody from a novel synthetic nanobody library
2022
·
Dmitri Dormeshkin
, Michail Shapira
, et al.
·
Frontiers in Immunology
·
15
State of the art and perspectives of chimeric antigen receptor T cells cell therapy for neuroblastoma
2024
·
Dzmitry Lutskovich
, Alexander Meleshko
, et al.
·
Cytotherapy
·
14
Case report: Rapid resolution of grade IV ICANS after first line intrathecal chemotherapy with methotrexate, cytarabine and dexamethasone
2024
·
Mikalai Katsin
, Tatsiana Shman
, et al.
·
Frontiers in Immunology
·
10
Safety and Immunogenicity of Combined DNA-Polyethylenimine and Oral Bacterial Idiotypic Vaccine for Patients with B-Cell Non-Hodgkin Lymphoma: A Pilot Study
2022
·
Alexander Meleshko
, Nadzeya Piatrouskaya
, et al.
·
Cancers
·
8
PDF
CD19 CAR T cell therapy BY19 for pediatric and adult patients with relapsed or refractory B cell neoplasms in Belarus: Phase 1 trial
2025
·
Mikalai Katsin
, Dmitri Dormeshkin
, et al.
·
Molecular Therapy Oncology
·
3
PDF
Design and Immunogenicity of SARS-CoV-2 DNA Vaccine Encoding RBD-PVXCP Fusion Protein
2023
·
Dmitri Dormeshkin
, Mikalai Katsin
, et al.
·
Vaccines
·
3
PDF
Safety and preliminary efficacy of combined lenalidomide and CD19 CAR T-cell therapy in relapsed/refractory CLL: A phase I study
2025
·
Mikalai Katsin
, Dmitri Dormeshkin
, et al.
·
Blood
·
1
PDF
Lenalidomide enhances CD19 CAR-T cell fitness and target-cell engagement in relapsed/refractory CLL
2026
·
Mikalai Katsin
, Valeria M. Stepanova
, et al.
·
medRxiv
PDF
Show more works
View as search
Works count:
9
Citation count:
74
H-index:
5
I10-index:
4
Year
Topic
Type